TY - JOUR
T1 - Antibody-mediated immunity against tuberculosis
T2 - Implications for vaccine development
AU - Achkar, Jacqueline M.
AU - Casadevall, Arturo
N1 - Funding Information:
This work was supported by funds from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; AI-067665 to J.M.A. and AI-033774, AI-052733, AI-033142 to A.C.); the National Heart, Lung, and Blood Institute (NHLBI; HL-059842 to A.C.); the Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine (AI-51519; J.M.A.); the Aeras TB Vaccine Foundation (J.M.A. and A.C.); and the Food and Drug Administration (FDA; 1U18 FD004012/01 to J.M.A.). A.C. is also the recipient of a Bill and Melinda Gates Grand Challenge award and a TB Vaccine Accelerator Program award. We thank Anke Ziegenbalg for her graphic assistance with the figure.
PY - 2013/3/13
Y1 - 2013/3/13
N2 - There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.
AB - There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.
UR - http://www.scopus.com/inward/record.url?scp=84875141413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875141413&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2013.02.009
DO - 10.1016/j.chom.2013.02.009
M3 - Review article
C2 - 23498951
AN - SCOPUS:84875141413
SN - 1931-3128
VL - 13
SP - 250
EP - 262
JO - Cell Host and Microbe
JF - Cell Host and Microbe
IS - 3
ER -